IMCAS 2025: New Galderma Phase IIIb Data Reinforce Rapid Onset and Long-lasting Aesthetic Improvement with RelabotulinumtoxinA (Relfydess)

2025年02月07日 21:24:29 来自: (0)参与

First results from the phase IIIb RELAX clinical trial reinforce the high and sustained efficacy of single treatment of RelabotulinumtoxinA (RelfydessTM) for moderate to severe frown lines (glabellar lines) beyond 6 months
These results reinforce RelabotulinumtoxinA’s 6-month clinical effect and rapid onset from Day 1 demonstrated in the phase III READY clinical trial program1,2
Data also show high and sustained patient satisfaction with treatment outcomes and appearance beyond 6 months1
Developed and manufactured by Galderma, RelabotulinumtoxinA is the first and only ready-to-use liquid neuromodulator developed using PEARLTM Technology that is optimized for simple volumetric dosing to increase ease-of-use3,4,5

ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SWX:GALD), the pure-play dermatology category leader, announced today results from its new phase IIIb RELAX clinical trial demonstrating the rapid onset and the long-lasting duration of aesthetic efficacy, as well as high patient satisfaction and increased confidence, using a single-dose of RelabotulinumtoxinA (Relfydess) to treat frown lines (glabellar lines)1. Galderma’s analysis was presented at the International Master Course on Aging Science (IMCAS) 2025 annual congress, held in Paris from January 30 to February 1, 2025.

Developed and manufactured by Galderma, RelabotulinumtoxinA is the first and only ready-to-use liquid neuromodulator created with PEARL Technology that is designed to preserve molecule integrity to deliver a highly active, innovative, complex-free molecule3,4,5. Previously announced data from the phase III READY clinical trial program demonstrated rapid onset as soon as Day 1 (reported by up to 39% of subjects) and long-lasting efficacy for 6 months (maintained by up to 75% of subjects) when using RelabotulinumtoxinA to treat frown lines and crow’s feet (lateral canthal lines) 2,6.

 

“We are proud to share our latest RelabotulinumtoxinA data, which reaffirms the sustained clinical effect and patient satisfaction observed in our READY clinical trial program. These findings, together with our proprietary PEARL Technology, reinforce RelabotulinumtoxinA as a safe, effective, and innovative treatment option, and uphold Galderma’s position at the forefront of aesthetic advancements.”

BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D.

GLOBAL HEAD OF R&D

GALDERMA

 
相关新闻
凤凰网友:你真叫我作呕
评论:恋爱需要实习,而两个人分手则需要练习!

搜狐网友:暖心 Vicious▽
评论:人生自古谁无死 , 要死也等你先死 。

天猫网友:遗忘。Forgotten.
评论:笑容是馈赠别人的见面礼,眼泪是洗涤自我的沐浴露。

其它网友:- 莫失莫忘/ 
评论:当今社会一瞥:男人女人化;女人小孩化;小孩宠物化;宠物贵族化;贵族痞子化;痞子玩文化;文化商业化。

本网网友:苏素/mmmmm
评论:既来之则安之,有福不享是傻子。

腾讯网友:身不亡wenod∕
评论:> 有人争取,就会有人失去

网易网友:执念/173yeah°
评论:赚钱像接露水那么辛苦,花钱却像流水那么迅速

天涯网友:红酒 高跟鞋 性感seduce
评论:我发自内心的同情灰太狼,编导你就给他一只羊吃呗

猫扑网友:寫不完的溫柔
评论:长大成人这件事最恐怖的地方之一,在于,你或许会变成自己曾经最看不起的那种人。

淘宝网友:羡慕嫉妒恨≈
评论:每次听到有人在吆喝回收废品我就想到把你卖了。

新闻转自网络媒体,如有侵权,请与我们联系:1160322105@qq.com责编:admin